Moxidectin

What is Moxidectin?

• Moxidectin is an anthelmintic used for the treatment of onchocerciasis due to Onchocerca volvulus.

What are the uses of this medicine?

• This medicine is used for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older.

How does this medicine work?

• The mechanism by which moxidectin exhibits its effect against O. volvulus is not known.
• Studies with other nematodes suggest that moxidectin binds to glutamate-gated chloride channels (GluCl), gamma-aminobutyric acid (GABA) receptors and/or ATP-binding cassette (ABC) transporters.
• This leads to increased permeability, influx of chloride ions, hyperpolarization and muscle paralysis.
• Additionally, there is a reduction in motility of all stages of the parasite, excretion of immunomodulatory proteins, and the fertility of both male and female adult worms.

Who Should Not Use this medicine ?

Limitations of Use:

• Moxidectin Tablets do not kill adult O. volvulus parasites. Follow-up is advised.
• The safety and efficacy of repeat administration of Moxidectin Tablets in patients with O. volvulus has not been studied.

What drug interactions can this medicine cause?

• No known drug interactions.

Is this medicine FDA approved?

• It was approved for use in the United States in 2018.

How should this medicine be used?

Recommended Dosage The recommended dosage of Moxidectin Tablet is a single dose of 8 mg (four 2 mg tablets) taken orally with or without food .

What are the dosage forms and brand names of this medicine?

This medicine is available in fallowing doasage form: As Tablets: 2 mg

This medicine is available in fallowing brand namesː

• MOXIDECTIN

What side effects can this medication cause?

The most common side effects of this medicine include:

• eosinophilia
• pruritus
• musculoskeletal pain
• headache
• lymphopenia
• tachycardia
• rash
• abdominal pain
• hypotension
• pyrexia
• leukocytosis
• influenza-like illness
• neutropenia
• cough
• lymph node pain
• dizziness
• diarrhea
• hyponatremia
• peripheral swelling

What special precautions should I follow?

Treatment with Moxidectin Tablets may cause cutaneous, ophthalmological and/or systemic reactions of varying severity (Mazzotti reaction). This may occur in patients with onchocerciasis following treatment with Moxidectin Tablets. Monitor patients for symptoms, including symptomatic orthostatic hypotension. Episodes of symptomatic orthostatic hypotension including inability to stand without support may occur in patients following treatment with Moxidectin Tablets. Serious or even fatal encephalopathy following treatment with Moxidectin Tablets may occur in patients co-infected with Loa loa. Assess patients for loiasis in Loa loa endemic areas prior to treatment. Patients with hyper-reactive onchodermatitis (sowda) may be more likely than others to experience severe edema and worsening of onchodermatitis following the use of Moxidectin Tablets. Symptomatic treatment has been used to manage patients who have experienced edema and worsening of onchodermatitis.

What to do in case of emergency/overdose?

Management for overdosage: No specific antidote is available for overdose with Moxidectin Tablets. If overdose occurs, the patient should be monitored for evidence of toxicity. Treatment of overdose with Moxidectin Tablets consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. Supportive therapy, if indicated, should include parenteral fluids and electrolytes, respiratory support (oxygen and mechanical ventilation if necessary) and pressor agents if clinically significant hypotension is present.

Can this medicine be used in pregnancy?

• Available data from clinical trials on the use of Moxidectin Tablets in pregnant women are insufficient to establish whether there is a moxidectin-associated risk for major birth defects and miscarriage.

Can this medicine be used in children?

• The safety and effectiveness of Moxidectin Tablets have been established in pediatric patients 12 years of age and older.
• The safety and effectiveness of Moxidectin Tablets in pediatric patients under 12 years of age has not been established.

What are the active and inactive ingredients in this medicine?

Active ingredients:

• MOXIDECTIN

Who manufactures and distributes this medicine?

• Packager: Medicines Development for Global Health

What should I know about storage and disposal of this medication?

• Store below 30°C (86°F).
• Protect from light.
• Once open, the full contents of the container should be used within 24 hours with any unused content discarded.

• Dailymed label info on Moxidectin
• FDA Moxidectin

Moxidectin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia